Response to Fionula Brennan's Commentary "A follow-up to 'Anti-cytokine therapy in chronic destructive arthritis' by Wim B van den Berg" by van den Berg, Wim B
ICE = IL-1b converting enzyme; IL = interleukin; RA = rheumatoid arthritis; TNF = tumour necrosis factor.
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In her commentary [1] on my recent review “Anti-cytokine
therapy in chronic destructive arthritis” [2], Fionula
Brennan raises a number of interesting discussion points.
A first issue regards the critical question of whether animal
models of arthritis resemble the human disease. Brennan
recognises that models and cytokine transgenic mice have
been a valuable tool to test hypotheses, but concludes
that they can never fully substitute for human rheumatoid
arthritis (RA). Although I have spent most of my recent
research on exploring the role of cytokines in murine arthri-
tis models, I fully agree with this statement.
Animal models can at best reflect elements of the human
disease and should be used as such. Great care has to be
taken with extrapolation of findings in a particular model to
human RA. When consistent observations have been
made in a whole range of arthritis models, however, it is
more likely that similar elements might apply to RA. Apart
from the consistent findings that anti-IL-1 treatment
blocked the progression to chronic erosive arthritis in all
models, the relevance of IL-1 as a crucial destructive
mediator and propagator of joint inflammation is further
underlined by the total lack of induction of chronic arthritis
and joint erosions in IL-1b-deficient mice, in whatever
arthritis model studied so far. In clear contrast, arthritis
and erosions were still found in most models when
induced in tumour necrosis factor (TNF)-deficient mice.
The apparent limitations of the mice transgenic for human
TNF, in which it was shown that the pathology is transmit-
ted through the IL-1 receptor pathway [3], are well taken.
Indeed, the transgene is expressed in synovial fibroblasts
[4], rather than in macrophages, which are the dominant
TNF-producing cells in human RA. Although the cellular
source of TNF differs in the transgenic synovial tissue,
induction by TNF of downstream mediators in other
(nearby) cells is of major importance, making the origin of
the initial producer cells less critical.
The group of George Kollias has extended their work on
TNF transgenics, with the elegant construction not only of
transgenic mice that selectively overexpress a membrane-
bound form of TNF (mTNF), but also of ‘normal’ mice that
carry just the mTNF and selectively express this form after
triggering. These mice show spontaneous [5] and induced
arthritis (my personal observation) respectively, demon-
strating that mTNF expression can be enough to drive the
arthritic process. The importance of cell–cell interactions
in the synovial tissue, with subsequent cytokine/enzyme
production, are further underlined by the work of the group
of Jean-Michel Dayer [6].
Some of the cartilage destruction occurs at sites of
pannus overgrowth, where synoviocyte–chondrocyte inter-
action might occur. In animal models as well as in human
RA, cartilage destruction is also seen away from pannus.
In the latter situation, traffic of cytokines and susceptibility
of chondrocytes to these cytokines are major determi-
nants. The higher potency of IL-1, compared to TNF, as a
catabolic factor for chondrocytes is not debated. Further-
more, as soluble TNF is a short-lived molecule, synovium-
derived TNF is unlikely to reach the chondrocytes in
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significant quantities. In this respect, IL-1 seems to be the
major effector molecule.
Receptor expression on chondrocytes and local cytokine
production are other determinants in the relative impor-
tance of TNF and IL-1. It becomes clear that TNF expres-
sion in arthritic cartilage can vary enormously, as recently
shown in articular cartilage obtained from late stage
osteoarthritis patients [7]. In fact, classification as high- or
low-TNF responder groups was suggested. Whether
similar subgroups can be identified in RA and whether the
existence of subgroups has consequences for an erosive
pathway driven more by TNF or by IL-1 remains to be seen.
In animal models, IL-1a is found in the inflamed joint only
at acute stages, probably linked to substantial cell death.
Neutralisation of IL-1a, in addition to IL-1b, is then needed.
In advanced stages of arthritis, massive cell death is not a
key event and IL-1b is the more abundant cytokine. In line
with this, antibodies to IL-1b alone are very effective in
treating established collagen arthritis [8], whereas ICE
inhibitors (which block maturation of IL-1b) also caused
significant suppression. IL-1b can be identified in
increased quantities in macrophages in the synovial tissue
of all RA patients, but the technology of immunostaining
does not allow accurate statements on membrane-associ-
ated IL-1a to be made. Therapeutic studies with high-
quality, neutralising antibodies to the IL-1 isoforms have to
be awaited. Anyway, such studies are needed to prove the
validity of IL-1b as a therapeutic target.
At present, clinical studies with novel ICE inhibitors are in
progress. Such inhibitors will not only prevent IL-1 matura-
tion, but will also inhibit the maturation of IL-18, an IL-1-
like molecule with the ability to induce TNF and IL-1 [9]. It
is expected that such inhibitors provide a dual hit. The
selectivity for caspase-1 and the pharmacokinetics remain
points of concern.
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